COVID-19 / Federal government / Funding / Partnerships / Science

Gaithersburg’s Novavax awarded $1.6B to further develop its coronavirus vaccine

The company will use the federal funds to move its COVID-19 vaccine candidate into the third phase of clinical trials, establish large-scale manufacturing and produce 100 million vaccine doses as planned.

A Novavax scientist conducing vaccine development research. (Courtesy Novavax)

Gaithersburg, Maryland-based Novavax, a clinical-stage biotech company that develops vaccines to prevent serious infectious diseases, has been awarded $1.6 billion to participate in a U.S. government program.

The 33-year-old company is currently conducting clinical trials for a COVID-19 vaccine while it prepares to produce up to 100 million vaccine doses by the end of the year. This award comes with Novavax’s selection to participate in Operation Warp Speed, a program operated by the federal government which aims to invest in companies prepared to deliver effective COVID-19 vaccines in 2021. The company will use the fresh funding to move its vaccine candidate into the third phase of clinical trials, establish large-scale manufacturing and produce 100 million vaccine doses as planned.

The company has never brought a product to market before, according to The New York Times.

“The pandemic has caused an unprecedented public health crisis, making it more important than ever that industry, government and funding entities join forces to defeat the novel coronavirus together,” said Novavax President and CEO Stanley C. Erck in a statement. “We are grateful to the U.S. government for its confidence in our technology platform, and are working tirelessly to develop and produce a vaccine for this global health crisis.”

As part of the partnership, Novavax must demonstrate that it can scale up manufacturing for its vaccine and transition to ongoing production, per a press release. During this time, the company will also determine how safe and efficient its vaccine is, with plans to run trials with up to 30,000 subjects this fall. The federal funding will also support Novavax’s plans to file a license with the U.S. Food and Drug Administration to administer its vaccine.

Back in May, Novavax conducted phase one and two clinical trials of its coronavirus vaccine on 130 healthy participants ages 18 to 59 in Australia. Safety results from these trials are expected to come in this month. These first two vaccine trials were financially supported by Norway’s Coalition for Epidemic Preparedness Innovations, which invested a total of $388 million. Novavax is manufacturing its coronavirus vaccine in Baltimore.

Th company’s stock price jumped by 31% on Monday after the news of its new funding from the federal government was announced, CNBC reported. So far this year, Novavax’ stock price has rose by 1,800%.

Series: Coronavirus

Before you go...

Please consider supporting to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

Our services Preferred partners The journalism fund

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!


Howard University’s Black Commerce Conference doubles in size for its return on Juneteenth

Welcome to Camp Apple Intelligence

Find out what type of heat wave you’re really in for with NOAA’s HeatRisk dashboard

How AI can revolutionize education's quest for truth

Technically Media